Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 5
2005 15
2006 18
2007 19
2008 25
2009 24
2010 19
2011 25
2012 19
2013 14
2014 18
2015 24
2016 17
2017 11
2018 18
2019 19
2020 30
2021 23
2022 25
2023 10

Text availability

Article attribute

Article type

Publication date

Search Results

330 results

Results by year

Filters applied: . Clear all
Page 1
Drugs for chronic insomnia.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2018 Dec 17;60(1562):201-205. Med Lett Drugs Ther. 2018. PMID: 30625122 Review. No abstract available.
Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis.
Kuriyama A, Honda M, Hayashino Y. Kuriyama A, et al. Sleep Med. 2014 Apr;15(4):385-92. doi: 10.1016/j.sleep.2013.11.788. Epub 2014 Feb 8. Sleep Med. 2014. PMID: 24656909 Review.
Our meta-analysis assessed the efficacy and safety of ramelteon for the treatment of insomnia in adults. We included both published and unpublished data from randomized placebo-controlled trials evaluating the efficacy of ramelteon in adults with insomnia in the ana …
Our meta-analysis assessed the efficacy and safety of ramelteon for the treatment of insomnia in adults. We included both published a …
Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial.
Hatta K, Kishi Y, Wada K, Takeuchi T, Odawara T, Usui C, Nakamura H; DELIRIA-J Group. Hatta K, et al. JAMA Psychiatry. 2014 Apr;71(4):397-403. doi: 10.1001/jamapsychiatry.2013.3320. JAMA Psychiatry. 2014. PMID: 24554232 Clinical Trial.
The Kaplan-Meier estimates of time to development of delirium were 6.94 (95% CI, 6.82-7.06) days for ramelteon and 5.74 (5.05-6.42) days for placebo. Comparison by log-rank test showed that the frequency of delirium was significantly lower in patients taking ramelteon …
The Kaplan-Meier estimates of time to development of delirium were 6.94 (95% CI, 6.82-7.06) days for ramelteon and 5.74 (5.05-6.42) d …
Melatonin.
Savage RA, Zafar N, Yohannan S, Miller JMM. Savage RA, et al. 2022 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. 2022 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 30521244 Free Books & Documents.
Consequently, melatonin is not officially FDA-approved for any indication. However, melatonin receptor agonists such as ramelteon and tasimelteon are FDA-approved for the treatment of insomnia. ...This activity will highlight the mechanism of action, adverse event profile, …
Consequently, melatonin is not officially FDA-approved for any indication. However, melatonin receptor agonists such as ramelteon and …
Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery.
Atkin T, Comai S, Gobbi G. Atkin T, et al. Pharmacol Rev. 2018 Apr;70(2):197-245. doi: 10.1124/pr.117.014381. Pharmacol Rev. 2018. PMID: 29487083 Review.
We analyzed the melatonergic agonist drugs, agomelatine, prolonged-release melatonin, ramelteon, and tasimelteon; the dual orexin receptor antagonist suvorexant; the modulators of the alpha(2)delta subunit of voltage-sensitive calcium channels, gabapentin and pregabalin; t …
We analyzed the melatonergic agonist drugs, agomelatine, prolonged-release melatonin, ramelteon, and tasimelteon; the dual orexin rec …
Menopause and Sleep Disorders.
Tandon VR, Sharma S, Mahajan A, Mahajan A, Tandon A. Tandon VR, et al. J Midlife Health. 2022 Jan-Mar;13(1):26-33. doi: 10.4103/jmh.jmh_18_22. Epub 2022 May 2. J Midlife Health. 2022. PMID: 35707298 Free PMC article. Review.
Tricyclic antidepressant, Selective Serotonin Reuptake Inhibitors (SSRI), Melatonin, Duloxetine, Fluoxetine, Imipramine, Nortriptyline or Amitriptyline and other drugs such as Eszopiclone, Escitalopram, Gabapentin, Quiteiapine, Citalopram, Mirtazapine followed by long-acting Mela …
Tricyclic antidepressant, Selective Serotonin Reuptake Inhibitors (SSRI), Melatonin, Duloxetine, Fluoxetine, Imipramine, Nortriptyline or Am …
MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective.
Liu J, Clough SJ, Hutchinson AJ, Adamah-Biassi EB, Popovska-Gorevski M, Dubocovich ML. Liu J, et al. Annu Rev Pharmacol Toxicol. 2016;56:361-83. doi: 10.1146/annurev-pharmtox-010814-124742. Epub 2015 Oct 23. Annu Rev Pharmacol Toxicol. 2016. PMID: 26514204 Free PMC article. Review.
This review describes the pharmacological properties of a slow-release melatonin preparation (i.e., Circadin) and synthetic ligands (i.e., agomelatine, ramelteon, tasimelteon), with emphasis on identifying specific therapeutic effects mediated through MT1 and MT2 receptor …
This review describes the pharmacological properties of a slow-release melatonin preparation (i.e., Circadin) and synthetic ligands (i.e., a …
Pharmacological Management of Nightmares Associated with Posttraumatic Stress Disorder.
Geldenhuys C, van den Heuvel LL, Steyn P, Seedat S. Geldenhuys C, et al. CNS Drugs. 2022 Jul;36(7):721-737. doi: 10.1007/s40263-022-00929-x. Epub 2022 Jun 10. CNS Drugs. 2022. PMID: 35688992 Review.
Evidence does not support the use of venlafaxine, beta-blockers, benzodiazepines, or sedative hypnotics. Novel agents such as ramelteon, cannabinoids, ketamine, psychedelic agents, and trihexyphenidyl have shown promising results. ...
Evidence does not support the use of venlafaxine, beta-blockers, benzodiazepines, or sedative hypnotics. Novel agents such as ramelteon …
Melatonin and its analogs in insomnia and depression.
Cardinali DP, Srinivasan V, Brzezinski A, Brown GM. Cardinali DP, et al. J Pineal Res. 2012 May;52(4):365-75. doi: 10.1111/j.1600-079X.2011.00962.x. Epub 2011 Sep 23. J Pineal Res. 2012. PMID: 21951153 Free article. Review.
Thus, attention has been focused either on the development of more potent melatonin analogs with prolonged effects or on the design of slow release melatonin preparations. The MT(1) and MT(2) melatonergic receptor ramelteon was effective in increasing total sleep time and …
Thus, attention has been focused either on the development of more potent melatonin analogs with prolonged effects or on the design of slow …
Circadian Rhythm and Melatonin in the Treatment of Depression.
Satyanarayanan SK, Su H, Lin YW, Su KP. Satyanarayanan SK, et al. Curr Pharm Des. 2018;24(22):2549-2555. doi: 10.2174/1381612824666180803112304. Curr Pharm Des. 2018. PMID: 30073921 Review.
RESULTS: Melatonin, a pleiotropic regulator molecule and its analogues (ramelteon, agomelatine, TIK-301, Neu- P11 and tasimelteon) have been observed to resynchronize the circadian rhythm and some were said to alleviate depressive symptoms in depressed subjects. ...
RESULTS: Melatonin, a pleiotropic regulator molecule and its analogues (ramelteon, agomelatine, TIK-301, Neu- P11 and tasimelteon) ha …
330 results